Jørgensen L N, Wille-Jørgensen P, Hauch O
Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark.
Br J Surg. 1993 Jun;80(6):689-704. doi: 10.1002/bjs.1800800607.
To evaluate the thromboprophylactic use of low molecular weight heparins (LMWHs), publications from 27 orthopaedic trials and 35 studies of patients undergoing general or gynaecological surgery were scrutinized and subjected to a partial meta-analysis. In orthopaedic surgery, LMWHs were superior to placebo or dextran and at least as efficient as unfractionated heparin in the prevention of deep vein thrombosis (DVT). Compared with unfractionated heparin, one of the LMWH preparations significantly reduced the total incidence of DVT. The rate of non-fatal pulmonary embolism was 0.49 per cent in patients receiving LMWH and 1.22 per cent in controls. Seven orthopaedic patients (0.15 per cent) died from pulmonary embolism, none of whom received LMWH. In general surgery, the LMWHs were at least as efficient as unfractionated heparin, with a trend towards a lower risk of pulmonary embolism with the former. Compared with unfractionated heparin, LMWHs did not reduce the postoperative mortality rate, nor did they cause haemorrhage. LMWHs provide safe and efficient prophylaxis by administration once daily.
为评估低分子量肝素(LMWHs)在血栓预防方面的应用,对27项骨科试验以及35项普通外科或妇科手术患者研究的出版物进行了审查,并进行了部分荟萃分析。在骨科手术中,低分子量肝素在预防深静脉血栓形成(DVT)方面优于安慰剂或右旋糖酐,且至少与普通肝素一样有效。与普通肝素相比,一种低分子量肝素制剂显著降低了深静脉血栓形成的总发生率。接受低分子量肝素治疗的患者非致命性肺栓塞发生率为0.49%,对照组为1.22%。7名骨科患者(0.15%)死于肺栓塞,其中无一例接受低分子量肝素治疗。在普通外科手术中,低分子量肝素至少与普通肝素一样有效,且前者有降低肺栓塞风险的趋势。与普通肝素相比,低分子量肝素并未降低术后死亡率,也未引起出血。低分子量肝素通过每日给药一次提供安全有效的预防作用。